Janssen
NICE approves Velcade
March 21, 2014Sales and Marketing Janssen, NHS, NICE, Velcade, myeloma
NICE has recommended Janssen’s proteasome inhibitor Velcade as an induction treatment for some patients with newly-diagnosed multiple myeloma. The draft …
FDA extends licence for Janssen’s Imbruvica
February 13, 2014Sales and Marketing FDA, Janssen, durect, imbruvica, leukaemia
Janssen and partner Pharmacyclics have been given an extended FDA approval for their new blood cancer treatment Imbruvica. The US …
J&J: we’re proud to top social media leaderboard
January 27, 2014Medical Communications, Sales and Marketing IMS, J&J, JJ, Janssen, digital, epatient, pharma
Johnson & Johnson says recognising the rise of the ePatient and being willing to share its corporate plans with the …
Imbruvica boost for Pharmacyclics
January 8, 2014Sales and Marketing Janssen, Pharmacyclics, imbruvica
Pharmacyclics and Janssen Biotech have received a huge boost as a late-stage trial of their first-in-class, oral blood cancer drug …
Janssen bets on stem cells
January 7, 2014Research and Development, Sales and Marketing CDC, Janssen, Stem cells, cap, capricor
US biotech Capricor Therapeutics is being backed by Janssen Biotech to the tune of hundreds of millions of dollars to …
FDA approves Olysio
November 25, 2013Sales and Marketing FDA, Janseen, Janssen, hep C, hepc, olysio, simeprevir
US regulators have approved Janssen Pharmaceuticals’ Olysio, a new therapy to treat chronic hepatitis C virus infection, after a priority …
Janssen/Pharmacyclics gain FDA nod for Imbruvica
November 14, 2013Sales and Marketing FDA, Janssen, Pharmacyclics, Revlimid, Velcade
The FDA has approved Janssen and Pharmacyclics’ Imbruvica to treat patients with mantle cell lymphoma (MCL), a rare and aggressive …
J&J hit with $2.2 billion fine
November 5, 2013Sales and Marketing J&J, JJ, Janssen, Risperdal, antipsychotic, fine
Johnson & Johnson has admitted promoting its big-selling antipsychotic drug Risperdal off-label, costing the firm $2.2 billion in fines. The …
Janssen agrees Zytiga deal
October 14, 2013Sales and Marketing AstraZeneca, Janssen, Zytiga
Janssen has agreed to co-promote its once-daily prostate cancer pill Zytiga with AstraZeneca in Japan for an undisclosed sum. A …
Janssen takes on GSK hep C drug
October 9, 2013Research and Development, Sales and Marketing GSK, GSK2336805, HCV, Janssen
Janssen Pharmaceuticals has acquired one of GlaxoSmithKline’s investigational hepatitis C treatments and will look at it in combination with various …
Hospira’s Inflectra approved in Europe
September 10, 2013Research and Development, Sales and Marketing Hospira, Janssen, Remicade, biosimilars, inflectra
Hospira has been the first firm to meet the European Commission’s approval for a biosimilar monoclonal antibody therapy with its …
Women in the pharma industry
September 3, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Johnson and Johnson, adams, women
In the past pharma has been accused of being too male-orientated in both the laboratory and the boardroom. The idea …
Remicade copies set for European entry
July 1, 2013Sales and Marketing CHMP, Hospira, Janssen, Remicade, arthritis, biosimilar
Janssen’s Remicade could soon come under generic pressure after a landmark recommendation by the CHMP. South Korean biotech Celltrion and …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
